Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
International Journal of Molecular Sciences
|
January 23, 2024
Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides
Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, et al.
ACS Omega
|
June 21, 2021
Stabilization of an <sup>211</sup>At-Labeled Antibody with Sodium Ascorbate
Shino Manabe, Hiroki Takashima, Kazunobu Ohnuki, et al.
Molecular Pharmaceutics
|
March 1, 2026
Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy
Hiroki Takashima, Ryo Tsumura, Yoshikatsu Koga, et al.
International Journal of Molecular Sciences
|
June 19, 2024
Preclinical Evaluation of Biodistribution and Toxicity of [<sup>211</sup>At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer
Tadashi Watabe, Kazuko Kaneda-Nakashima, Yuichiro Kadonaga, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 12, 2023
Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with <sup>89</sup>Zr or <sup>211</sup>At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
Tadashi Watabe, Kazuya Kabayama, Sadahiro Naka, et al.
Cancer Science
|
February 19, 2021
Radioimmunotherapy with an <sup>211</sup> At-labeled anti-tissue factor antibody protected by sodium ascorbate
Hiroki Takashima, Yoshikatsu Koga, Shino Manabe, et al.
International Journal of Molecular Sciences
|
November 27, 2024
Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target
Kentaro Hisada, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, et al.
Inorganic Chemistry
|
October 15, 2013
Measurement of the Md3+/Md2+ reduction potential studied with flow electrolytic chromatography
Atsushi Toyoshima, Zijie Li, Masato Asai, et al.
Nature Chemistry
|
February 16, 2021
Co-precipitation behaviour of single atoms of rutherfordium in basic solutions
Yoshitaka Kasamatsu, Keigo Toyomura, Hiromitsu Haba, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 25, 2025
First-in-Human Study of [<sup>211</sup>At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)
Tadashi Watabe, Kosuke Mukai, Sadahiro Naka, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
International Journal of Molecular Sciences
|
January 23, 2024
Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides
Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, et al.
ACS Omega
|
June 21, 2021
Stabilization of an <sup>211</sup>At-Labeled Antibody with Sodium Ascorbate
Shino Manabe, Hiroki Takashima, Kazunobu Ohnuki, et al.
Molecular Pharmaceutics
|
March 1, 2026
Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy
Hiroki Takashima, Ryo Tsumura, Yoshikatsu Koga, et al.
International Journal of Molecular Sciences
|
June 19, 2024
Preclinical Evaluation of Biodistribution and Toxicity of [<sup>211</sup>At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer
Tadashi Watabe, Kazuko Kaneda-Nakashima, Yuichiro Kadonaga, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 12, 2023
Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with <sup>89</sup>Zr or <sup>211</sup>At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
Tadashi Watabe, Kazuya Kabayama, Sadahiro Naka, et al.
Cancer Science
|
February 19, 2021
Radioimmunotherapy with an <sup>211</sup> At-labeled anti-tissue factor antibody protected by sodium ascorbate
Hiroki Takashima, Yoshikatsu Koga, Shino Manabe, et al.
International Journal of Molecular Sciences
|
November 27, 2024
Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target
Kentaro Hisada, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, et al.
Inorganic Chemistry
|
October 15, 2013
Measurement of the Md3+/Md2+ reduction potential studied with flow electrolytic chromatography
Atsushi Toyoshima, Zijie Li, Masato Asai, et al.
Nature Chemistry
|
February 16, 2021
Co-precipitation behaviour of single atoms of rutherfordium in basic solutions
Yoshitaka Kasamatsu, Keigo Toyomura, Hiromitsu Haba, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 25, 2025
First-in-Human Study of [<sup>211</sup>At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)
Tadashi Watabe, Kosuke Mukai, Sadahiro Naka, et al.
Page
of 6